|
|
|
|
| LEADER |
03259nam a2200325 u 4500 |
| 001 |
EB000944072 |
| 003 |
EBX01000000000000000737662 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 020 |
|
|
|a 0309298148
|
| 020 |
|
|
|a 9780309298148
|
| 100 |
1 |
|
|a Friedman, Douglas C.
|
| 245 |
0 |
0 |
|a Technological challenges in antibiotic discovery and development
|h Elektronische Ressource
|b a workshop summary
|c Douglas Friedman and Joe Alper, rapporteurs ; Chemical Sciences Roundtable, Board on Chemical Sciences and Technology, Division on Earth and Life Studies, National Research Council of the National Academies
|
| 260 |
|
|
|a Washington, D.C.
|b National Academies Press
|c 2014, [2014]
|
| 300 |
|
|
|a xiii, 34 pages
|b color illustrations
|c 28 cm
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Bacterial Infections / drug therapy
|
| 653 |
|
|
|a Drug Discovery
|
| 653 |
|
|
|a Anti-Bacterial Agents / therapeutic use
|
| 653 |
|
|
|a Drug Resistance, Bacterial
|
| 700 |
1 |
|
|a Alper, Joe
|e [author]
|
| 710 |
2 |
|
|a National Research Council (U.S.)
|b Chemical Sciences Roundtable.
|
| 710 |
2 |
|
|a Technological Challenges in Antibiotic Discovery and Development (Workshop) (2013, Washington, D.C.)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK190333
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 856 |
4 |
0 |
|u http://www.nap.edu/catalog.php?record_id=18616
|3 Volltext
|n Provider site
|3 Volltext
|
| 082 |
0 |
|
|a 615.3/29
|
| 520 |
|
|
|a "Technological Challenges in Antibiotic Discovery and Development is the summary of a workshop convened by the Chemical Sciences Roundtable in September 2013 to explore the current state of antibiotic discovery and examine the technology available to facilitate development. Through formal presentations and panel discussions, participants from academia, industry, federal research agencies discussed the technical challenges present and the incentives and disincentives industry faces in antibiotic development, and identified novel approaches to antibiotic discovery. Antibiotic resistance is a serious and growing problem in modern medicine and it is emerging as a pre-eminent public health threat. Each year in the United States alone, at least two million acquire serious infections with bacteria that are resistant to one or more antibiotics, and at least 23,000 people die annually as a direct result of these antibiotic-resistant infections. In addition to the toll on human life, antibiotic-resistant infections add considerable and avoidable costs to the already overburdened U.S. health care system. This report explores the challenges in overcoming antibiotic resistance, screening for new antibiotics, and delivering them to the sites of infection in the body. The report also discusses a path forward to develop the next generation of potent antimicrobial compounds capable of once again tilting the battle against microbial pathogens in favor of humans. Technological Challenges in Antibiotic Discovery and Development gives a broad view of the landscape of antibiotic development and the technological challenges and barriers to be overcome."--Publisher's description
|